CipherBio Weekly Digest: Week of Feb 10 – Feb 16, 2022
This week our life science funding digest reports $2.77B in deals and $391.90M in Series A. We also added 105 companies and 42 investors to our platform.
$2.96B
Deals
$789.04M
Series A
$647.7M
Later Rounds
$900M
M&A/IPOs
105
New Companies on CipherBio
42
New Investors on CipherBio
Sign Up For Your Free Account ➜
Top Deals This Week
Upstream Bio, Cambridge-based biotech, raises $200M in Series A round led by Orbimed. A FoodTech company Next Gen Foods raises $100M in Series A from Temasek Holdings, K3 Ventures, GGV Capital and others.
Leyden Labs raises $140M in Series B led by Casdin Capital and GV. Also in Series B
Third Harmonic Bio raises $105M led by General Atlantic and BVF Partners.
Kallyope gets $150M in Series D led by Mubadala Investment Company and The Column Group.
Collegium Pharmaceutical acquires BioDelivery Sciences in an all-cash deal worth up to $604M.
Company | Round | Amount |
---|---|---|
Upstream Bio | Series A | $200M |
Series A | $100M | |
Series B | $140M | |
Series B | $105M | |
Series D | $150M | |
Acquisition | $604M |
Funds Raised This Week
ACME Capital, San Francisco VC, raises $300M in ACME Fund IV from undisclosed investors.
Asia Healthcare Holdings(AHH) raises $170M in Wealth Fund GIC from undisclosed investors. Unovis Asset Management closes $166M Unovis Asset Management’s Fund II from Unigestion, Invest-NL, Griffith Foods and others.
This Week’s Lead Investors in Top Rounds
Lead investors this week are Orbimed, Temasek, Casdin Capital, GV, General Atlantic, BVF Partners, Mubadala Investment Company and The Column Group.
This Week in Clinical Phases
In phase 1 Maze Therapeutics announces trial of MZE001 for Pompe Disease. Belgium-based
Oxurion announces phase 2 clinical trial of THR-149.
Revive Therapeutics is in phase 3 trial of Bucillamine.
Motus GI got the FDA Clearance for its Pure-Vu® EVS System.
Company | Product and Clinical Phase | Indications |
---|---|---|
MZE001, Phase 1 | Pompe Disease | |
THR-149, Phase 2 | Diabetic Macular Edema | |
Bucillamine, Phase 3 | Liver Diseases, Autoimmune Hepatitis, COVID-19 | |
Pure-Vu® EVS System, FDA Cleared | Gastrointestinal Diseases |
Starfield, food & science technology, raised $100M in Series B round led by Primavera Capital Group, Lightspeed China Partners and Joy Capital.
FlipDish raised $100M in Series C led by Tencent. In AgTech
MycoWorks raised $125M in Series C to build a new alt-leather factory. WayCool raised $117M in Series D led by LightRock, LightBox, FMO and others.
105 Life Science Companies Added
This week we added 154 funding events, 105 life science companies and 42 investors.
To get all the latest life science deals and VC funding data delivered straight to your inbox weekly become a CipherBio PRO member.